Page 2481 - Williams Hematology ( PDFDrive )

2452 Index Index 2453

IMPDH1/2, 200 parasitic. See Parasitic infections chronic, 279, 290–291
Impotence, history of, 5 platelet function in, 1855–1856 history, 279
IMPs (intramembrane particles), 1047 purpura and, 2104–2105, 2104f, 2105f molecular changes in, 1976–1979
Inborn errors of metabolism, 890 recurrent, workup of, 1034f acute, 1978
Inclusion body β-thalassemia, 732 red cell antigens and susceptibility to, 2340 adhesion molecules, 1978
Incomplete infarction, 2269 susceptibility to chronic, 1978
Indian blood group/antigens, 2332t, 2337, in acute lymphoblastic leukemia, 1514 immediate, 1976–1978
2346t in chronic granulomatous disease, inflammatory mediators, 1979t
Indian hedgehog (IHH), 54 1029–1030, 1031t leukocyte-endothelial cell matrix
Indomethacin in chronic lymphocytic leukemia, 1528, interactions promoting
antiplatelet effects, 404, 2075 1530, 1541 coagulation, 1979
for patent ductus arteriosus, 107 in Gaucher disease, 1125 leukocyte-platelet and endothelial
Induced pluripotent stem cells (iPSCs), in hairy cell leukemia, 1555–1556, 1559 cell-platelet interactions, 1977t,
448–449 in HIV infection, 1240–1241, 1241t 1978–1979
Induced proximity model, 205 in immunodeficiency diseases. See monocytes/macrophages in, 1083–1086
Inducible caspase-0 protein (iCasp9), 440, Immunodeficiency diseases cytokine-induced priming and,
440f in myeloma, 1745–1746 1085–1086, 1086f
Induction of hepatic ALASI, 901 in sickle cell disease, 773 G-protein–coupled receptors in, 1059,
I-negative phenotype (i adult), 2343 in thalassemias, 742 1060t
Infants. See Newborns/infants thrombotic microangiopathy and, immunomodulation of, 1084, 1084f
Infection 2260–2261 innate activation of, 1084
atherosclerosis and, 2288 viral. See Viral infections recruitment of, 1083–1084, 1084f
bacterial. See Bacterial infections Infectious mononucleosis. See Mononucleosis natural anticoagulants and, 2202
blood group association, 2341–2342t syndromes neutrophilia and, 1000–1001, 1000t
bone marrow infiltration, 33, 33f Inferior vena cava filter, 2278 platelets in, 1855–1856
disseminated intravascular coagulation Infertility. See Reproductive system disorders regulation, 286–290, 286t
and, 2204t, 2207 Infiltrative lesions, history of, 6 coagulation system in, 290
eosinophilia in, 955t Inflammasome pathway, 299, 300f complement system in, 289–290
fungal. See Fungal infections Inflammasomes, 284, 1063, 1065f, 1066f cytokines and chemokines in, 287–288,
hemolytic anemia caused by. Inflammation. See also Inflammatory 287t, 288t
See Hemolytic anemia, response inflammatory lipids in, 288–289
infection-related anemia of. See Anemia of inflammation kinins in, 289
in hemophilia A, 2126 (AI) lysosomal granule constituents in, 287
in immunocompromised host, 383–389 in atherosclerosis. See Atherosclerosis, neutrophil apoptosis in, 285
bacterial, 369, 383, 384–385, 388–389 inflammation and proteinase-activated receptors in, 290
cytomegalovirus, 1267–1268 chronic, 279, 290–291 reactive nitrogen intermediates in,
diagnosis, 384 in disseminated intravascular coagulation, 286–287
fungal, 369, 383, 385–386, 389 2200, 2201 reactive oxygen intermediates in, 286
after hematopoietic cell transplantation, endothelial, 2283 vasoactive amines in, 289
357, 368–370, 389 frailty and, 137 repair process and, 280, 290–291
mycobacterial, 384, 386 hepcidin regulation by, 622 resolution, 285–286
prevention, 388–389 monocytosis and, 1097 in sickle cell disease, 765
risk factors, 383 thrombocytosis in, 2035–2036 suppressive effects on erythropoietin
treatment, 384–388 Inflammatory bowel disease, 1229 precursors, 550
adjustments, 386 Inflammatory lipids, 288–289 Infliximab, 1359
duration, 386 Inflammatory response, 279–291. See also Influenza, 1064f
of fever after recovery from Inflammation Inhibitor of apoptosis (IAP) proteins,
chemotherapy, 386, 388 acute, 279, 280–285 207–208, 210, 1858–1859t
initial, 384–386, 387–388t acute-phase response, 284–285 Inhibitor of κB kinase γ (IKKγ), 298
outpatient, 388 hemodynamic changes in, 280, 281f Inhibitory signals, 253
viral, 369–370, 383–384, 386, 389 leukocyte adhesion and transmigration Innate immunity, 293–304
lymphocytopenia and, 1204–1205 in, 280–283, 282f, 282t activation of adaptive immunity and,
lymphocytosis and, 1204 leukocyte chemotaxis and activation in, 303–304
monocytosis and, 1097 283–284 vs. adaptive immunity, 293, 294t
neutropenia and, 991, 997 basophilia and, 971 atherosclerosis and, 2285–2286
neutrophilia and, 1000–1001, 1000t characteristics, 279–280 dendritic cells and, 307

Kaushansky_index_p2393-2506.indd 2452 9/21/15 3:22 PM